PT Siloam International Hospitals Tbk operates a network of hospitals in Indonesia. The company manages and operates multiple hospitals in Jadebotabek. Siloam Hospitals makes investments in both technology and medical staff to offer various medical services. The company also manages Centers of Excellence that address medical cases requiring complex treatment. The company derives its revenue from inpatient and outpatient services. Inpatient services derive revenue from medical support and medical specialist services, drugs and medical supplies, and inpatient rooms. Outpatient services derive revenue from delivery of medical support and medical specialist services, drugs and medical supplies, and hospital facilities. Inpatient services are responsible for a majority of the company's revenue.
1996
14.6K+
LTM Revenue $786M
LTM EBITDA $194M
$1.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Siloam Hospitals has a last 12-month revenue (LTM) of $786M and a last 12-month EBITDA of $194M.
In the most recent fiscal year, Siloam Hospitals achieved revenue of $747M and an EBITDA of $139M.
Siloam Hospitals expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Siloam Hospitals valuation multiples based on analyst estimatesLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Revenue | $786M | XXX | $747M | XXX | XXX | XXX |
Gross Profit | $313M | XXX | $297M | XXX | XXX | XXX |
Gross Margin | 40% | XXX | 40% | XXX | XXX | XXX |
EBITDA | $194M | XXX | $139M | XXX | XXX | XXX |
EBITDA Margin | 25% | XXX | 19% | XXX | XXX | XXX |
EBIT | $124M | XXX | $112M | XXX | XXX | XXX |
EBIT Margin | 16% | XXX | 15% | XXX | XXX | XXX |
Net Profit | $69.2M | XXX | $55.2M | XXX | XXX | XXX |
Net Margin | 9% | XXX | 7% | XXX | XXX | XXX |
Net Debt | XXX | XXX | $28.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of June 27, 2025, Siloam Hospitals's stock price is IDR 2190 (or $0).
Siloam Hospitals has current market cap of IDR 28.44T (or $1.7B), and EV of IDR 29.48T (or $1.8B).
See Siloam Hospitals trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$1.8B | $1.7B | XXX | XXX | XXX | XXX | $0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of June 27, 2025, Siloam Hospitals has market cap of $1.7B and EV of $1.8B.
Siloam Hospitals's trades at 2.4x EV/Revenue multiple, and 12.9x EV/EBITDA.
Equity research analysts estimate Siloam Hospitals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Siloam Hospitals has a P/E ratio of 25.1x.
See valuation multiples for Siloam Hospitals and 12K+ public compsLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Market cap (current) | $1.7B | XXX | $1.7B | XXX | XXX | XXX |
EV (current) | $1.8B | XXX | $1.8B | XXX | XXX | XXX |
EV/Revenue | 2.3x | XXX | 2.4x | XXX | XXX | XXX |
EV/EBITDA | 9.3x | XXX | 12.9x | XXX | XXX | XXX |
EV/EBIT | 14.6x | XXX | 16.1x | XXX | XXX | XXX |
EV/Gross Profit | 5.8x | XXX | n/a | XXX | XXX | XXX |
P/E | 25.1x | XXX | 31.5x | XXX | XXX | XXX |
EV/FCF | 71.5x | XXX | 42.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSiloam Hospitals's last 12 month revenue growth is 10%
Siloam Hospitals's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $13K for the same period.
Siloam Hospitals's rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Siloam Hospitals's rule of X is 49% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Siloam Hospitals and other 12K+ public compsLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Revenue Growth | 10% | XXX | 10% | XXX | XXX | XXX |
EBITDA Margin | 25% | XXX | 19% | XXX | XXX | XXX |
EBITDA Growth | 11% | XXX | 14% | XXX | XXX | XXX |
Rule of 40 | 33% | XXX | 29% | XXX | XXX | XXX |
Bessemer Rule of X | XXX | XXX | 49% | XXX | XXX | XXX |
Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
Opex per Employee | XXX | XXX | $13K | XXX | XXX | XXX |
S&M Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Opex to Revenue | XXX | XXX | 25% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Burjeel Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
PureHealth | XXX | XXX | XXX | XXX | XXX | XXX |
Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
Ramsay Health | XXX | XXX | XXX | XXX | XXX | XXX |
Athens Medical Centre | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Siloam Hospitals acquired XXX companies to date.
Last acquisition by Siloam Hospitals was XXXXXXXX, XXXXX XXXXX XXXXXX . Siloam Hospitals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free TrialWhen was Siloam Hospitals founded? | Siloam Hospitals was founded in 1996. |
Where is Siloam Hospitals headquartered? | Siloam Hospitals is headquartered in Indonesia. |
How many employees does Siloam Hospitals have? | As of today, Siloam Hospitals has 14.6K+ employees. |
Is Siloam Hospitals publicy listed? | Yes, Siloam Hospitals is a public company listed on IDX. |
What is the stock symbol of Siloam Hospitals? | Siloam Hospitals trades under SILO ticker. |
When did Siloam Hospitals go public? | Siloam Hospitals went public in 2013. |
Who are competitors of Siloam Hospitals? | Similar companies to Siloam Hospitals include e.g. Burjeel Holdings, PureHealth, Integral Diagnostics, Ramsay Health. |
What is the current market cap of Siloam Hospitals? | Siloam Hospitals's current market cap is $1.7B |
What is the current revenue of Siloam Hospitals? | Siloam Hospitals's last 12 months revenue is $786M. |
What is the current revenue growth of Siloam Hospitals? | Siloam Hospitals revenue growth (NTM/LTM) is 10%. |
What is the current EV/Revenue multiple of Siloam Hospitals? | Current revenue multiple of Siloam Hospitals is 2.3x. |
Is Siloam Hospitals profitable? | Yes, Siloam Hospitals is EBITDA-positive (as of the last 12 months). |
What is the current EBITDA of Siloam Hospitals? | Siloam Hospitals's last 12 months EBITDA is $194M. |
What is Siloam Hospitals's EBITDA margin? | Siloam Hospitals's last 12 months EBITDA margin is 25%. |
What is the current EV/EBITDA multiple of Siloam Hospitals? | Current EBITDA multiple of Siloam Hospitals is 9.3x. |
What is the current FCF of Siloam Hospitals? | Siloam Hospitals's last 12 months FCF is $25.2M. |
What is Siloam Hospitals's FCF margin? | Siloam Hospitals's last 12 months FCF margin is 3%. |
What is the current EV/FCF multiple of Siloam Hospitals? | Current FCF multiple of Siloam Hospitals is 71.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.